-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$11.506.78% Upside
Mesoblast Limited Frequently Asked Questions
-
What analysts cover Mesoblast Limited?
Mesoblast Limited has been rated by research analysts at Maxim Group, Piper Sandler in the past 90 days.